Company research
ProPhase Labs, Inc.
CIK 868278Updated Sep 24, 2026
SecurityPRPH · OTC · equity
Name history
QUIGLEY CORP · through May 18, 2010
PRPH price & chart
Loading TradingView…
OTC:PRPH on TradingView ↗About the company
We are a next-generation biotech, genomics and consumer products company. We are also focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds, and diagnostics.
In the news
SEC disclosures
ProPhase Labs, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
NT 10-Q filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
10-Q/A filing
10-Q/A filing
Show 5 more recent filings
10-Q filing
10-K filing
NT 10-Q filing
NT 10-K filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 59,871,000Source | 63,200,000Source | 91,927,000Source | 87,648,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 7,288,000Source |
| GoodwillUSD | 3,968,000Source | 5,231,000Source | 5,231,000Source | 5,709,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,167,000Source | 9,750,000Source | 12,333,000Source | 8,475,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 90,000Source | 678,000Source | 1,609,000Source | 9,109,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,536,000Source | 20,058,000Source | 36,313,000Source | 37,054,000Source |
| Inventory, NetUSD | 70,000Source | 1,143,000Source | 3,841,000Source | 3,976,000Source |
| Assets, CurrentUSD | 3,150,000Source | 30,637,000Source | 47,585,000Source | 60,833,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,454,000Source | 2,615,000Source | 2,155,000Source | 2,366,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 4,115,000Source | 4,572,000Source | 4,059,000Source |
| Other Assets, NoncurrentUSD | 2,000Source | 310,000Source | 1,163,000Source | 1,163,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 56,363,000Source | 55,847,000Source | 42,544,000Source | 24,017,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 4,000Source | 23,000Source | 18,000Source | 16,000Source |
| Additional Paid in CapitalUSD | 126,481,000Source | 129,921,000Source | 118,694,000Source | 109,138,000Source |
| Retained Earnings (Accumulated Deficit)USD | -73,136,000Source | -58,393,000Source | -5,029,000Source | 11,753,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -198,000Source | -198,000Source | -300,000Source | 757,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,508,000Source | 7,353,000Source | 49,383,000Source | 63,631,000Source |
| Liabilities and EquityUSD | 59,871,000Source | 63,200,000Source | 91,927,000Source | 87,648,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 53,081,000Source | 32,134,000Source | 20,857,000Source | 16,075,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 1,214,000Source | 953,000Source | 301,000Source |
| Accounts Payable, CurrentUSD | — | 13,717,000Source | 9,383,000Source | 5,905,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 3,762,000Source | 4,237,000Source | 4,259,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 0Source | 224,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | 1,536,000Source | 20,058,000Source | 36,313,000Source | 37,054,000Source |
| Accrued Liabilities, CurrentUSD | 1,885,000Source | 1,945,000Source | 1,445,000Source | 714,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 700,000Source | 5,300,000Source | — |
| Deferred Revenue, CurrentUSD | — | — | 2,382,000Source | 2,499,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | 224,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 2,924,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 4,832,000Source | 6,187,000Source | 6,277,000Source | 4,718,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,893,000Source | 3,638,000Source | 3,536,000Source | 3,986,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -736,000Source | -4,738,000Source | 68,000Source | 4,498,000Source |
| Increase (Decrease) in InventoriesUSD | -313,000Source | -1,360,000Source | -135,000Source | -702,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 7,150,000Source | -7,074,000Source | -138,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,344,000Source | -17,538,000Source | -11,348,000Source | 28,551,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 0Source | 2,904,000Source | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 920,000Source | 2,422,000Source | -1,369,000Source | -2,077,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 0Source | 5,379,000Source | — |
| Payments for Repurchase of Common StockUSD | — | 0Source | 588,000Source | 2,152,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,836,000Source | 14,185,000Source | 5,757,000Source | -26,023,000Source |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -588,000Source | -931,000Source | -6,960,000Source | 451,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 678,000Source | 2,149,000Source | 9,100,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,161,000Source | 3,105,000Source | 932,000Source | 763,000Source |
| Income Taxes Paid, NetUSD | 1,645,000Source | 1,126,000Source | 3,000,000Source | 1,696,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,900,000Source | 3,600,000Source | 3,500,000Source | 4,500,000Source |
| Amortization of Intangible AssetsUSD | 2,600,000Source | 2,600,000Source | 2,900,000Source | 2,400,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 700,000Source | 5,300,000Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | -18,000Source | 22,000Source | -354,000Source |
| DepreciationUSD | 2,200,000Source | 4,200,000Source | 3,100,000Source | 2,300,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 437,000Source | — | — | — |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxUSD | 8,746,000Source | — | — | — |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of TaxUSD | -102,000Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | 127,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | -76,000Source |
| Gain (Loss) on Sale of PropertiesUSD | — | 91,000Source | 23,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -955,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | -1,357,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 838,000Source | -333,000Source | — | — |
| General and Administrative ExpenseUSD | 19,324,000Source | 37,885,000Source | 34,502,000Source | 34,385,000Source |
| GoodwillUSD | 3,968,000Source | 5,231,000Source | 5,231,000Source | 5,709,000Source |
| Goodwill, Impairment LossUSD | 1,300,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -23,387,000Source | -49,525,000Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 8,644,000Source | -3,839,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -166,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 7,195,000Source | -6,018,000Source | 4,445,000Source |
| InterestExpenseNonoperatingUSD | 6,933,000Source | 3,350,000Source | — | — |
| Inventory Write-downUSD | 196,000Source | — | — | -78,000Source |
| Investment Income, InterestUSD | — | — | — | 153,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | 932,000Source |
| Net Income (Loss) Attributable to ParentUSD | -14,743,000Source | -53,364,000Source | -16,782,000Source | 18,463,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -16,782,000Source | 18,464,000Source |
| Operating ExpensesUSD | 19,431,000Source | 38,479,000Source | 37,852,000Source | 47,059,000Source |
| Operating Lease, ExpenseUSD | 422,000Source | — | — | 816,000Source |
| Other Nonoperating Income (Expense)USD | -174,000Source | -18,000Source | 10,000Source | — |
| Proceeds from Issuance of Common StockUSD | 3,558,000Source | 7,594,000Source | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 0Source | 3,374,000Source | 4,168,000Source | 7,120,000Source |
| Provision for Loan, Lease, and Other LossesUSD | — | 0Source | 91,000Source | 6,163,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 4,345,000Source | 6,770,000Source | 44,384,000Source | 122,647,000Source |
| Cost of RevenueUSD | 2,961,000Source | 6,920,000Source | 28,145,000Source | 51,993,000Source |
| Operating Income (Loss)USD | -18,047,000Source | -38,629,000Source | -21,613,000Source | 23,595,000Source |
| Other Nonoperating Income (Expense)USD | -174,000Source | -18,000Source | 10,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -23,387,000Source | -42,330,000Source | -22,800,000Source | 22,908,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 7,195,000Source | -6,018,000Source | 4,445,000Source |
| Net Income (Loss) Attributable to ParentUSD | -14,743,000Source | -53,364,000Source | -16,782,000Source | 18,463,000Source |
| Earnings Per Share, BasicUSD per share | -1.74Source | -2.61Source | -0.98Source | 1.17Source |
| Earnings Per Share, DilutedUSD per share | -1.74Source | -2.61Source | -0.98Source | 1.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,489,000Source | 20,463,000Source | 17,207,000Source | 15,845,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,489,000Source | 20,463,000Source | 17,207,000Source | 18,651,000Source |
| Interest Expense (non-operating)USD | 6,933,000Source | 3,350,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,600,000Source | 2,600,000Source | 2,900,000Source | 2,400,000Source |
| Current Income Tax Expense (Benefit)USD | — | 45,000Source | 1,056,000Source | 4,583,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,250,000Source | 6,187,000Source | 6,049,000Source | 4,542,000Source |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of TaxUSD | -102,000Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | -76,000Source |
| General and Administrative ExpenseUSD | 19,324,000Source | 37,885,000Source | 34,502,000Source | 34,385,000Source |
| Goodwill, Impairment LossUSD | 1,300,000Source | — | — | — |
| Gross ProfitUSD | 1,384,000Source | -150,000Source | 16,239,000Source | 70,654,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -23,387,000Source | -49,525,000Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -2.75Source | -2.42Source | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -2.75Source | -2.42Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 8,644,000Source | -3,839,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -166,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 1,275,000Source | 764,000Source |
| Interest Income, OtherUSD | — | 0Source | 78,000Source | — |
| Investment Income, InterestUSD | — | — | — | 153,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -16,782,000Source | 18,464,000Source |
| Operating ExpensesUSD | 19,431,000Source | 38,479,000Source | 37,852,000Source | 47,059,000Source |
| Operating Lease, ExpenseUSD | 422,000Source | — | — | 816,000Source |
| Research and Development ExpenseUSD | 107,000Source | 594,000Source | 1,418,000Source | 652,000Source |
Offerings
Registration 333-291001
Filing attachments
ex99-1.htm · 8-K · 2026-01-02
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stanley Higgins Associate Vice President Nasdaq Listing Qualifications By Electronic Delivery to: karkus@prophaselabs.com December 29, 2025 Ted Karkus Principal Executive Officer ProPhase Labs, Inc. 626 RXR Plaza 6th Floor Uniondale, New York 11556 Re: ProPhase Labs, Inc. (the “Company”) – Staff Determination Nasdaq Symbol: PRPH Dear Ted Karkus: As you are aware, on December 26, 2024, Staff notified the Co…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-19
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET. ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed Special Counsel to Launch Litigation Against Insurance Companies. First Settlement Completed. Reiterates $50 MI…
Read attachment ↗ex107.htm · S-1 · 2025-10-21
Exhibit 107 Calculation of Filing Fee Tables Form S-1 ProPhase Labs, Inc. Table 1: Newly Registered Securities The following table sets forth the calculation of the registration fee in accordance with Rules 457(c) and 457(g) under the Securities Act of 1933, as amended. The shares of common stock are being registered for resale by the selling stockholders identified in this prospectus. We will not receive any of the proceeds from the sale of such shares. Security Securit…
Read attachment ↗ex99-1.htm · 8-K · 2025-08-19
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders UNIONDALE, NY, August 19, 2025 (GLOBE NEWSWIRE) - ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement (“DEF 14A”) with the U.S. Securities and Exchange Commission (“SEC”) on Friday, August 15, 2025 and …
Read attachment ↗ex99-1.htm · 8-K · 2025-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET…
Read attachment ↗ex99-1.htm · 8-K · 2025-07-29
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, July 29, 2025 (GLOBE NEWSWIRE) - ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”)…
Read attachment ↗